Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
Version v9-FR | Version v2-EN | |
---|---|---|
Language | French | English |
Date Updated | 2019-09-10 | 2019-07-18 |
Drug Identification Number | 02431130 | 02431130 |
Brand name | VINORELBINE INJECTION, USP | VINORELBINE INJECTION, USP |
Common or Proper name | Vinorelbine for Injection | Vinorelbine for Injection |
Company Name | GENERIC MEDICAL PARTNERS INC | GENERIC MEDICAL PARTNERS INC |
Ingredients | VINORELBINE | VINORELBINE |
Strength(s) | 10MG | 10MG |
Dosage form(s) | SOLUTION | SOLUTION |
Route of administration | INTRAVENOUS | INTRAVENOUS |
Packaging size | 5 ml Vial. Each pack contains one vial. | 5 ml Vial. Each pack contains one vial. |
ATC code | L01CA | L01CA |
ATC description | PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS | PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS |
Reason for shortage | Demand increase for the drug. | Demand increase for the drug. |
Anticipated start date | 2019-07-01 | 2019-07-18 |
Actual start date | 2019-07-01 | 2019-07-01 |
Estimated end date | 2019-10-01 | 2020-07-01 |
Actual end date | ||
Shortage status | Actual shortage | Actual shortage |
Tier 3 Status | No | No |
Company comments | GMP has removed the 75% allocation on Vinorelbine 10 mg/ml 5 ml vials for all contracted accounts and all direct orders. A further increase in stock level is anticipated at the end of September that should result in all restrictions on supply being removed. | GMP is seeking to increase production to meet national demand by October 2019. As interim step, GMP has implemented a 75% allocation on all orders on all contracted and any other direct orders that are able to be serviced until production meets demand. |
Health Canada comments |